{
    "2019-02-19": [
        [
            {
                "time": "",
                "original_text": "大摩：医药股面对政策逆风 首选信达生物(01801.HK)等",
                "features": {
                    "keywords": [
                        "医药股",
                        "政策逆风",
                        "信达生物"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报: 国务院新年第一会任务部署, 癌症、罕见病产业链将受益",
                "features": {
                    "keywords": [
                        "医药行业",
                        "国务院",
                        "癌症",
                        "罕见病",
                        "产业链",
                        "受益"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}